Meet Patricia
70-year-old retired lawyer and volunteer who cherishes her self-reliance and visiting with her grandchildren.
With my kidney cancer, I couldn’t volunteer anymore but that’s fine with me. If I can keep caring for myself and visiting with my grandkids, then that’s all I need.”
MEDICAL HISTORY: Found blood in her urine and a lump in her abdomen
INITIAL DIAGNOSIS: Advanced renal cell carcinoma (RCC) with a clear cell histology and lytic bone metastases; scheduled for nephrectomy
CURRENT STATUS:
- RCC is metastatic and Patricia is treatment naïve
- ECOG performance status: 2
- MSKCC risk: poor
- Karnofsky performance status (KPS): 50%
In COMPARZ, VOTRIENT demonstrated efficacy across a wide range of patients1,2:
12% of patients had a poor MSKCC risk
42% of patients had ≥3 involved organs
Patient age ranged from 18 to 88 years
When choosing first-line treatment, what therapy do you consider?
Hypothetical patient case study.
References: 1. VOTRIENT [summary of product characteristics]. Camberley, UK: Novartis Europharm Limited; February 2018. 2. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722-731.
